Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Ever since Frederiksen took office in Denmark in 2019, the second woman and youngest person ever to become prime minister in ...

A reduced supply is pushing up prices, especially for ownership properties in the capital, according to figures from Finans Danmark, Ritzau reports. In Copenhagen, the average asking price for ...

FC Copenhagen will start qualifying for the Champions League. The opponent will be the winner of the match between Differdange from Luxembourg and Drita from Kosovo. Sports director Sune Smith-Nielsen ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance ...

Novo Nordisk stock has multiple catalysts that could soon reverse is slide.

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.” The supercomputer, named Gefion ...

Novo Nordisk reported that it is advancing amycretin to a phase 3 study. Image source: Getty Images. The company is making the move after receiving feedback on earlier-stage testing.